Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin

Cerebrovasc Dis. 2000 Nov-Dec;10(6):424-30. doi: 10.1159/000016102.

Abstract

The role of thrombin as a spasmogen after subarachnoid hemorrhage was evaluated using the intrathecally administered thrombin inhibitor hirudin, released from a drug delivery system (DDS) based on collagen in a canine vasospasm model. The DDS was implanted into the cisterna magna with autologous blood in the hirudin-treated group. The reduction in the angiographical diameter of the basilar artery was only 19% in the hirudin-treated group on day 7, showing a significant difference between hirudin-treated and nontreated groups (p < 0.01). These results suggest that thrombin is an important cause of vasospasm. The collagen DDS has great potential for treatment in the cerebrospinal fluid milieu.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antithrombins / cerebrospinal fluid
  • Antithrombins / pharmacokinetics*
  • Basilar Artery / drug effects
  • Basilar Artery / pathology
  • Cerebral Angiography
  • Cisterna Magna
  • Collagen
  • Dogs
  • Drug Delivery Systems / methods*
  • Drug Implants
  • Female
  • Hirudins / cerebrospinal fluid
  • Hirudins / pharmacokinetics*
  • Injections, Spinal
  • Male
  • Subarachnoid Hemorrhage / drug therapy
  • Subarachnoid Hemorrhage / pathology
  • Subarachnoid Space / pathology
  • Vasospasm, Intracranial / drug therapy*
  • Vasospasm, Intracranial / pathology

Substances

  • Antithrombins
  • Drug Implants
  • Hirudins
  • Collagen